SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Roque Vitor | EVP & Chief Financial Officer | 2026-09-02 | Tax withholding | 190 | $0 |
| Feld Michael | EVP, Chief Revenue Officer | 2026-08-26 | Open-market sell 10b5-1 | 165 | $31K |
| Feld Michael | EVP, Chief Revenue Officer | 2026-08-20 | Tax withholding | 1049 | $0 |
| Polen Thomas E Jr | Chairman, CEO and President, Director | 2026-08-13 | Option exercise 10b5-1 | 43278 | $7.2M |
| Polen Thomas E Jr | Chairman, CEO and President, Director | 2026-08-13 | D 10b5-1 | 39126 | $7.2M |
| Polen Thomas E Jr | Chairman, CEO and President, Director | 2026-08-13 | Open-market sell 10b5-1 | 4152 | $768K |
| Goette Roland | EVP and President, EMEA | 2026-08-11 | Open-market sell | 2438 | $441K |
| Feld Michael | EVP, Chief Revenue Officer | 2026-07-27 | Open-market sell 10b5-1 | 75 | $12K |
| Muhsin Bilal | EVP & President Connected Care | 2026-07-02 | Tax withholding | 1935 | $0 |
| Muhsin Bilal | EVP & President Connected Care | 2026-07-01 | Grant/award | 14342 | $0 |
| Feld Michael | EVP, Chief Revenue Officer | 2026-06-26 | Open-market sell 10b5-1 | 75 | $11K |
| Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 2026-06-24 | Open-market sell 10b5-1 | 1100 | $160K |
| Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 2026-06-10 | Open-market sell 10b5-1 | 1100 | $167K |
| Menziuso Peter | EVP and President, BDI | 2026-06-01 | Grant/award | 14258 | $0 |
| Polen Thomas E Jr | Chairman, CEO and President, Director | 2026-06-01 | Option exercise 10b5-1 | 20209 | $2.5M |
| Polen Thomas E Jr | Chairman, CEO and President, Director | 2026-06-01 | D 10b5-1 | 17445 | $2.5M |
| Polen Thomas E Jr | Chairman, CEO and President, Director | 2026-06-01 | Open-market sell 10b5-1 | 2764 | $405K |
| Feld Michael | EVP, Chief Revenue Officer | 2026-05-26 | Open-market sell 10b5-1 | 75 | $11K |
| Roque Vitor | EVP & Chief Financial Officer | 2026-05-07 | Grant/award | 1721 | $0 |
| Feld Michael | EVP, Chief Revenue Officer | 2026-04-27 | Open-market sell 10b5-1 | 74 | $11K |
Fiscal period ending 2025-09-30 versus 2024-09-30 — view filing on EDGAR →
A transformative and high-risk divestiture of the Biosciences/Diagnostics business to Waters — with a 39.2% equity stake, tax-free status uncertainty, and material break costs — dominates the risk picture alongside pervasive worsening across six distinct themes. New tariff exposure with quantifiable FY2026 impact, loss of well-known seasoned issuer status impairing refinancing, escalating AI and cybersecurity risks, stricter EPA ethylene oxide limits, realized government funding reductions, and expanded supply chain vulnerabilities collectively represent a broad and substantive deterioration in the risk profile.
12 company-specific · 4 common-mode
Material new risk: proposed divestiture of Biosciences/Diagnostics business to Waters with 39.2% equity stake in combined entity. Significant transaction risk, regulatory/IRS approval uncertainty, and material costs if deal fails.
Risks Relating to the Proposed Combination of Our Biosciences and Diagnostics Solutions Business with Waters The proposed combination of our Biosciences and Diagnostic Solutions business with Waters…
Material M&A risk: announced separation and combination with Waters creates operational disruption, management distraction, transaction costs, and operational restrictions on a business segment.
The announcement and pendency of the combination of our Biosciences and Diagnostic Solutions business with Waters could cause disruptions in our business. The completion of the separation of our…
New disclosure of material M&A risk: separation and combination of Biosciences/Diagnostic Solutions with Waters. Identifies failure-to-realize benefits, transition service burdens, and potential significant tax liabilities if deal loses tax-free status.
We may not realize some or all of the expected benefits of the combination of our Biosciences and Diagnostic Solutions business with Waters. If the separation of our Biosciences and Diagnostic…
New specific tariff risk disclosed: U.S. tariffs expected to adversely impact FY2026 operating expenses with limited mitigation. Section 232 investigation adds policy uncertainty. Material quantifiable impact.
Our international operations subject us to certain business risks. A substantial amount of our sales come from our operations outside the U.S., and we intend to continue to pursue growth…
Loss of "well-known seasoned issuer" status due to SEC Order materially impairs refinancing ability and increases debt servicing risk.
Risks Relating to Our Indebtedness We may not be able to service all of our indebtedness. We depend on cash on hand and cash flows from operations to make scheduled debt payments. However, our…
Added specific CMS Competitive Bidding Program expansion risk with concrete pricing pressure and supplier attrition concerns, plus Medicare/Medicaid legislative uncertainty.
Market dynamics, changes in reimbursement practices and coverage policies, third-party payer cost containment measures and health insurance coverage levels could affect demand for our products and…
Company disclosed actual reduction in government funding in FY2025 and added specific risks: federal shutdown, debt ceiling, agency downsizing. Concrete evidence of realized risk.
Reductions in customers’ research budgets or government funding may adversely affect our business. We sell products to researchers at pharmaceutical and biotechnology companies, academic…
EPA finalized stricter ethylene oxide exposure limits and monitoring requirements with compliance deadlines 60 days to 10 years. Regulatory burden increased materially with new occupational exposure limits and engineering controls.
Interruption of our manufacturing or sterilization operations could adversely affect our business. We have manufacturing sites all over the world. In some instances, however, the manufacturing of…
New specific competitive threat: oral GLP-1 medications as alternative therapies. Also added tariffs and U.S. policy changes as new cost/demand pressures.
The medical technology industry is very competitive. We are a global company that faces significant competition from a wide range of existing competitors and new market entrants. These include large…
Added explicit sole-supplier risk language and tariffs/U.S. government shutdown as new disruption factors, escalating supply chain vulnerability disclosure.
A reduction or interruption in the supply of certain raw materials and components could adversely affect our operating results. We purchase many different types of raw materials and components used…
Added explicit litigation and financial penalty risk ("subject to litigation, substantial fines and other damages"), supply chain interruption specificity, and regulatory non-compliance consequences. Escalates from reputational/market risk to legal and operational liability.
Climate change and related sustainability efforts, or legal, regulatory or market measures to address these efforts, could adversely affect our business, financial condition or results of operations.…
Added M&A integration risk exposure and explicit mention of financial reserves and disclosure obligations from recalls—substantive escalation of product quality risk.
Defects or quality issues associated with our products and related regulatory actions could adversely affect our results of operations and financial statements. The design, manufacture and marketing…
New disclosure of material AI risks: regulatory action, legal liability, IP issues, cybersecurity, and competitive disadvantage if not adopted timely.
The development, deployment and use of AI in our products and business operations generally could result in regulatory action, legal liability, operational challenges or reputational harm and our…
New explicit disclosure of tariff and import/export licensing risks; removal of inflation moderation language; addition of U.S. federal funding impact on healthcare demand.
Business, Economic and Industry Risks Global economic conditions, including inflation and supply chain disruptions, could continue to adversely affect our operations. General global economic…
Escalated AI-specific cybersecurity risks, expanded threat descriptions (real-time detection language, malicious AI use), and strengthened consequence language (damages/fines, cash flows impact).
Operational Risks Cybersecurity incidents and breaches or breakdowns of our information and technology systems or infrastructure could have a material adverse effect on our operations. We rely on a…
New disclosure of AI/emerging tech regulatory risk increasing R&D burden and IP protection difficulty—substantive operational and competitive concern.
Our operations are dependent in part on patents and other intellectual property assets. Many of our businesses rely on patent, trademark and other intellectual property assets. These intellectual…
BD issued a press release on August 6, 2026 announcing third quarter fiscal 2026 financial results, including revenue of $5.0 billion (5.4% reported growth), GAAP diluted EPS of $1.64, and adjusted diluted EPS of $3.23. The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes segment results, geographic performance, and updated full-year guidance, all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments, informed BD of his intention to retire effective October 2, 2026, after more than 20 years with the company. The filing also discloses an organizational restructuring whereby BioPharma Systems will report directly to the CEO following his departure.
View raw filing on EDGAR →BD discloses resumption of ChloraPrep™ and PurPrep™ shipments after a voluntary hold in response to an FDA Warning Letter for the El Paso manufacturing facility. While the disclosure emphasizes acceptable testing results and no patient safety signals, the underlying regulatory action (FDA Warning Letter) and product shipment disruption are material to investors assessing operational and regulatory risk, even though the immediate disclosure is framed positively.
View raw filing on EDGAR →BD subsidiary issued €600 million in senior unsecured notes with full guarantee from the parent company to refinance existing debt and fund general corporate purposes.
View raw filing on EDGAR →